Bristol-Myers Squibb Company
SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
Last updated:
Abstract:
Disclosed are compounds of Formula (I): ##STR00001## or a salt thereof, wherein: R.sub.1, R.sub.2, R.sub.4, R.sub.5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK.alpha.) and diacylglycerol kinase zeta (DGK.zeta.), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
Status:
Application
Type:
Utility
Filling date:
27 Aug 2020
Issue date:
4 Mar 2021